In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417.

@article{Haluska2006InVA,
  title={In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417.},
  author={Paul J Haluska and Joan M. Carboni and David A. Loegering and Francis Y. F. Lee and Mark D Wittman and Mark G Saulnier and David B Frennesson and Kimberly R. Kalli and Cheryl A. Conover and R. Attar and Scott H. Kaufmann and Marco M. Gottardis and Charles E Erlichman},
  journal={Cancer research},
  year={2006},
  volume={66 1},
  pages={362-71}
}
The insulin-like growth factor receptor (IGF-IR) and insulin receptor are either overactivated and/or overexpressed in a wide range of tumor types and contribute to tumorigenicity, proliferation, metastasis, and drug resistance. Here, we show that BMS-554417, a novel small molecule developed as an inhibitor of IGF-IR, inhibits IGF-IR and insulin receptor kinase activity and proliferation in vitro, and reduces tumor xenograft size in vivo. In a series of carcinoma cell lines, the IC50 for… CONTINUE READING
72 Citations
56 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 72 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 56 references

Similar Papers

Loading similar papers…